IP Library Granted Patent US 9,161,933
Granted Patent B2
US 9,161,933 · App. 13/139,673 · Granted Oct 20, 2015

Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,161,933
App. No.
13/139,673
Granted
Oct 20, 2015
Kind
B2
Abstract

The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof, which exhibits high dissolution rates of amlodipine and losartan even under a low pH condition and improved storage stability.

Claims (17)

1. A solid pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof,

wherein amlodipine or a pharmaceutically acceptable salt thereof is of granular form, and losartan or a pharmaceutically acceptable salt thereof is of granule form, wherein the granule of amlodipine or a pharmaceutically acceptable salt thereof and the granule of losartan or a pharmaceutically acceptable salt thereof are separated from each other;

wherein the composition comprises losartan or a pharmaceutically acceptable salt thereof in an amount ranging from 5 to 22.3% by weight based on the total weight of the composition;

wherein the composition comprises a granule form of losartan of which the percentage of a fine granule passing through a 75 μm mesh is below 50%;

wherein the dissolution rate of amlodipine in the solid pharmaceutical composition is 80% or more thereof in 30 minutes at a pH range of 1.0 to 2.0; and

wherein the dissolution rate of losartan in the solid pharmaceutical composition is 80% or more thereof in 30 minutes at a pH range of 1.0 to 2.0.

2. The composition of claim 1 , which comprises a granule form of losartan of which the percentage of a fine granule passing through a 75 μm mesh is below 25%.

3. The composition of claim 2 , which comprises a granule form of losartan of which the percentage of a fine granule passing through a 75 μm mesh is below 10%.

4. The composition of claim 1 , wherein the pharmaceutically acceptable salt of amlodipine is amlodipine camsylate.

5. A method for preparing the solid composition of claim 1 comprising amlodipine in a granule form and losartan in a granule form, said amlodipine granules and losartan granules being separated from each other, which comprises the steps of:

a) granulating and drying a mixture of losartan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient to obtain losartan granules;

b) granulating and drying a mixture of amlodipine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient to obtain amlodipine granules; and

c) mixing the losartan granules obtained in step a) with the amlodipine granules obtained in step b) to give the composition,

wherein the solid composition comprises losartan or a pharmaceutically acceptable salt thereof in an amount ranging from 5 to 22.3% by weight based on the total weight of the composition;

wherein the composition comprises a granule form of losartan of which the percentage of a fine granule passing through a 75 μm mesh is below 50%;

wherein the dissolution rate of amlodipine in the solid pharmaceutical composition is 80% or more thereof in 30 minutes at a pH range of 1.0 to 2.0; and

wherein the dissolution rate of losartan in the solid pharmaceutical composition is 80% or more thereof in 30 minutes at a pH range of 1.0 to 2.0.

Assignments (2)
CHANGE OF NAME Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2011
From: PARK, JAE HYUN; KIM, KYEONG SOO; YIM, HO TAEK
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 026443/0655 →